© 2021 Celcuity, Inc. All rights reserved.
Licensure: CLIA ID #: 24D2098245 / CAP #: 9387225
Corporate Overview

We are a clinical-stage biotechnology company seeking to extend the lives of cancer patients by pursuing an integrated companion diagnostic (CDx) and therapeutic (Rx) strategy that leverages our CELsignia CDx platform. CELsignia is uniquely able to analyze live patient tumor cells to identify new groups of cancer patients likely to benefit from targeted therapies.

Celcuity Headquarters
16305 – 36th Avenue North
Suite 100
Minneapolis, MN 55446